Behavior of Scoliosis During Growth in Children with Osteogenesis Imperfecta

被引:45
|
作者
Anissipour, Alireza K. [1 ]
Hammerberg, Kim W. [1 ]
Caudill, Angela [1 ]
Kostiuk, Theodore [1 ]
Tarima, Sergey [1 ]
Zhao, Heather Shi [1 ]
Krzak, Joseph J. [1 ]
Smith, Peter A. [1 ]
机构
[1] Shriners Hosp Crippled Children, Chicago, IL USA
来源
关键词
INTRAVENOUS PAMIDRONATE TREATMENT; SPINE; COMPLICATIONS; DEFORMITY; DISEASE; AGE;
D O I
10.2106/JBJS.L.01596
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Spinal deformities are common in patients with osteogenesis imperfecta, a heritable disorder that causes bone fragility. The purpose of this study was to describe the behavior of spinal curvature during growth in patients with osteogenesis imperfecta and establish its relationship to disease severity and medical treatment with bisphosphonates. Methods: The medical records and radiographs of 316 patients with osteogenesis imperfecta were retrospectively reviewed. The severity of osteogenesis imperfecta Was classified with the modified Sillence classification. Serial curve measurements were recorded throughout the follow-up period for each patient with scoliosis. Regression analysis was used to determine the effect of disease severity (Sillence type), patient age, and bisphosphonate treatment on the progression of scoliosis as measured with the Cobb method. Results: Of the 316 patients with osteogenesis imperfecta, 157 had associated scoliosis, a prevalence of 50%. Scoliosis prevalence (68%) and mean progression rate (6 degrees per year) were the highest in the group of patients with the most severe osteogenesis imperfecta (modified Sillence type III). A group with intermediate osteogenesis imperfecta severity, modified Sillence type IV, demonstrated intermediate scoliosis values (54%, 4 degrees per year). The patient group with the mildest form of osteogenesis imperfecta, modified Sillence type I, had the lowest scoliosis prevalence (39%) and rate of progression (1 degrees per year). Early treatment-before the patient reached the age of six years-of type-III osteogenesis imperfecta with bisphosphonate therapy decreased the curve progression rate by 3.8 degrees per year, which was a significant decrease. Bisphosphonate treatment had no demonstrated beneficial effect on curve behavior in patients with other types of osteogenesis imperfecta or in patients of older age. Conclusions: The prevalence of scoliosis in association with osteogenesis imperfecta is high. Progression rates of scoliosis in children with osteogenesis imperfecta are variable, depending on the Sillence type of osteogenesis imperfecta. High. rates of scoliosis progression in type-III and type-IV osteogenesis imperfecta contrast with a benign course in type I. Bisphosphonate therapy initiated before the patient reaches the age of six years can modulate curve progression in type-Ill osteogenesis imperfecta.
引用
收藏
页码:237 / 243
页数:7
相关论文
共 50 条
  • [31] The moral experiences of children with osteogenesis imperfecta
    Wang, Yi Wen
    Carnevale, Franco A.
    Ezcurra, Maria
    Chougui, Khadidja
    Bilodeau, Claudette
    Siedlikowski, Sophia
    Tsimicalis, Argerie
    NURSING ETHICS, 2022, 29 (7-8) : 1773 - 1791
  • [32] Hearing loss in children with osteogenesis imperfecta
    Kaija Kuurila
    Reidar Grénman
    Reijo Johansson
    Ilkka Kaitila
    European Journal of Pediatrics, 2000, 159 : 515 - 519
  • [33] Risedronate pharmacokinetics in children with osteogenesis imperfecta
    Thompson, GA
    Burgio, DE
    Bishop, N
    Russell, DA
    Sun, LA
    BONE, 2005, 36 : S82 - S82
  • [34] Cardiovascular Involvement in Children with Osteogenesis Imperfecta
    Karamifar, Hamdollah
    Ilkhanipoor, Homa
    Ajami, Gholamhossein
    Karamizadeh, Zohreh
    Amirhakimi, Gholamhossein
    Shakiba, Ali-Mohammad
    IRANIAN JOURNAL OF PEDIATRICS, 2013, 23 (05) : 513 - 518
  • [35] VERTEBRAL FRACTURES IN CHILDREN WITH OSTEOGENESIS IMPERFECTA
    Vadzianava, V.
    Pachkaila, A.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S510 - S511
  • [36] Alendronate treatment in children with osteogenesis imperfecta
    Akcay, Teoman
    Turan, Serap
    Guran, Tulay
    Bereket, Abdullaii
    INDIAN PEDIATRICS, 2008, 45 (02) : 105 - 109
  • [37] SURGICAL TREATMENT OF OSTEOGENESIS IMPERFECTA IN CHILDREN
    KRAUSE, M
    LANGENBECKS ARCHIV FUR CHIRURGIE, 1972, 331 (04): : 357 - 365
  • [38] OSTEOGENESIS IMPERFECTA AND OSTEOGENESIS IMPERFECTA CYSTICA
    FAIRBANK, HAT
    JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1948, 30 (01): : 164 - 186
  • [39] Surgical blood loss during femoral rodding in children with osteogenesis imperfecta
    Pichard, Carmen P.
    Robinson, Raymond E.
    Skolasky, Richard L.
    Fedarko, Neal S.
    Leet, Arabella I.
    JOURNAL OF CHILDRENS ORTHOPAEDICS, 2009, 3 (04) : 301 - 305
  • [40] Help on the horizon for children with osteogenesis imperfecta?
    Bradbury, J
    LANCET, 1999, 353 (9155): : 815 - 815